Anbio Biotechnology income statement

In fiscal 2025, Anbio Biotechnology reported revenue of $8.6m, up 5.6% on the year before, operating income of $5.8m (a 66.7% margin) and net income of $6.4m, or $0.15 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Anbio Biotechnology: income statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	24	7	8	9
Cost of revenue	11	3	2	1
Gross profit	13	3	6	8
Research and development	0	0	0	0
Selling, general and administrative	2	1	3	2
Operating income	10	2	2	6
Interest expense	0	—	—	—
Income before tax	10	2	2	6
Income tax	—	0	0	0
Net income	10	2	2	6
Diluted EPS	$50056.00	$0.05	$0.06	$0.15
Diluted shares (average)	—	43m	42m	44m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NNNN vs NUWE MLSS vs NNNN NMTC vs NNNN NNNN vs XAIR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Anbio Biotechnology's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Anbio Biotechnology.